Literature DB >> 28683573

Multimodal Lentiviral Vectors for Pharmacologically Controlled Switching Between Constitutive Single Gene Expression and Tetracycline-Regulated Multiple Gene Collaboration.

Maike Stahlhut1,2, Axel Schambach1,2,3, Olga S Kustikova1,2.   

Abstract

Multimodal lentiviral vectors (LVs) allow switching between constitutive and tetracycline-regulated gene co-expressions in genetically modified cells. Transduction of murine primary hematopoietic progenitor cells (HPCs) with multimodal LVs in the absence of doxycycline ensures the constitutive expression of gene of interest 1 (GOI1) only. In the presence of doxycycline, induced tetracycline-regulated expression of a second GOI (GOI2) allows evaluation of the collaboration between two genes. Drug removal retains constitutive expression, which allows the contribution of an individual gene into created networks to be studied. Doxycycline-dependent switching can be tracked via fluorescent markers coupled to constitutive and tetracycline-regulated GOIs. This article describes transduction of murine primary HPCs with different doses of multimodal LVs, distinct cytokine conditions, and their influence on the number and viability of cells co-expressing both collaborating GOIs upon doxycycline induction. A 2-week protocol is provided for multimodal LV production, titer determination, and evaluation of tetracycline responsive promoter background activity in a murine fibroblast cell line. The power of this model to assess the dose/time/order-controlled contribution of single and multiple genes into hematopoietic networks opens new routes in reprogramming, stem cell, and leukemia biology.

Entities:  

Keywords:  constitutive and tetracycline-regulated; fate tracking; genetic modification of HSCs and HPCs; lentiviral vectors

Mesh:

Substances:

Year:  2017        PMID: 28683573      PMCID: PMC5568180          DOI: 10.1089/hgtb.2017.073

Source DB:  PubMed          Journal:  Hum Gene Ther Methods        ISSN: 1946-6536            Impact factor:   2.396


  37 in total

1.  Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population.

Authors:  Olga S Kustikova; Anke Wahlers; Klaus Kuhlcke; Birgit Stahle; Axel R Zander; Christopher Baum; Boris Fehse
Journal:  Blood       Date:  2003-07-24       Impact factor: 22.113

2.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

Authors:  M Gossen; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

3.  Retroviral and transposon-based tet-regulated all-in-one vectors with reduced background expression and improved dynamic range.

Authors:  Niels Heinz; Axel Schambach; Melanie Galla; Tobias Maetzig; Christopher Baum; Rainer Loew; Bernhard Schiedlmeier
Journal:  Hum Gene Ther       Date:  2010-12-19       Impact factor: 5.695

4.  Retroviral insertion site analysis in dominant haematopoietic clones.

Authors:  Olga S Kustikova; Ute Modlich; Boris Fehse
Journal:  Methods Mol Biol       Date:  2009

5.  Lentiviral vector design and imaging approaches to visualize the early stages of cellular reprogramming.

Authors:  Eva Warlich; Johannes Kuehle; Tobias Cantz; Martijn H Brugman; Tobias Maetzig; Melanie Galla; Adam A Filipczyk; Stephan Halle; Hannes Klump; Hans R Schöler; Christopher Baum; Timm Schroeder; Axel Schambach
Journal:  Mol Ther       Date:  2011-02-01       Impact factor: 11.454

6.  Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia.

Authors:  U Thorsteinsdottir; E Kroon; L Jerome; F Blasi; G Sauvageau
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

7.  Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.

Authors:  Axel Schambach; Jens Bohne; Saurabh Chandra; Elke Will; Geoffrey P Margison; David A Williams; Christopher Baum
Journal:  Mol Ther       Date:  2005-10-12       Impact factor: 11.454

8.  HOXA10 is a critical regulator for hematopoietic stem cells and erythroid/megakaryocyte development.

Authors:  Mattias Magnusson; Ann C M Brun; Noriko Miyake; Jonas Larsson; Mats Ehinger; Jon Mar Bjornsson; Anton Wutz; Mikael Sigvardsson; Stefan Karlsson
Journal:  Blood       Date:  2007-01-18       Impact factor: 22.113

9.  Activation of Evi1 inhibits cell cycle progression and differentiation of hematopoietic progenitor cells.

Authors:  O S Kustikova; A Schwarzer; M Stahlhut; M H Brugman; T Neumann; M Yang; Z Li; A Schambach; N Heinz; S Gerdes; I Roeder; T C Ha; D Steinemann; B Schlegelberger; C Baum
Journal:  Leukemia       Date:  2012-12-05       Impact factor: 11.528

10.  Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes.

Authors:  Torsten A Konrad; Anna Karger; Hubert Hackl; Ilse Schwarzinger; Irene Herbacek; Rotraud Wieser
Journal:  J Leukoc Biol       Date:  2009-07-15       Impact factor: 4.962

View more
  1 in total

1.  Conditionally immortalised leukaemia initiating cells co-expressing Hoxa9/Meis1 demonstrate microenvironmental adaptation properties ex vivo while maintaining myelomonocytic memory.

Authors:  Maike Stahlhut; Teng Cheong Ha; Ekaterina Takmakova; Michael A Morgan; Adrian Schwarzer; Dirk Schaudien; Matthias Eder; Axel Schambach; Olga S Kustikova
Journal:  Sci Rep       Date:  2021-03-05       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.